Pro Medicus Ltd banner

Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 133.84 AUD -0.74% Market Closed
Market Cap: AU$14B

P/E

59.6
Current
64%
Cheaper
vs 3-y average of 163.7

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
59.6
=
Market Cap
AU$12.1B
/
Net Income
AU$234.7m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
59.6
=
Market Cap
AU$12.1B
/
Net Income
AU$234.7m

Valuation Scenarios

Pro Medicus Ltd is trading below its 3-year average

If P/E returns to its 3-Year Average (163.7), the stock would be worth AU$367.77 (175% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-63%
Maximum Upside
+175%
Average Upside
66%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 59.6 AU$133.84
0%
3-Year Average 163.7 AU$367.77
+175%
5-Year Average 163.7 AU$367.77
+175%
Industry Average 45.2 AU$101.44
-24%
Country Average 22.3 AU$50.03
-63%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
AU$12.1B
/
Jan 2026
AU$234.7m
=
59.6
Current
AU$12.1B
/
Jun 2026
AU$178m
=
67.8
Forward
AU$12.1B
/
Jun 2027
AU$199.5m
=
60.5
Forward
AU$12.1B
/
Jun 2028
AU$248.5m
=
48.6
Forward
AU$12.1B
/
Jun 2029
AU$275.1m
=
43.9
Forward
AU$12.1B
/
Jun 2030
AU$241.6m
=
49.9
Forward
AU$12.1B
/
Jun 2031
AU$260.3m
=
46.4
Forward
AU$12.1B
/
Jun 2032
AU$280.1m
=
43.1
Forward
AU$12.1B
/
Jun 2033
AU$299.9m
=
40.2
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Higher than 83% of companies in Australia
Percentile
83nd
Based on 1 271 companies
83nd percentile
59.6
Low
0 — 15.9
Typical Range
15.9 — 36.3
High
36.3 —
Distribution Statistics
Australia
Min 0
30th Percentile 15.9
Median 22.3
70th Percentile 36.3
Max 5 709.2

Pro Medicus Ltd
Glance View

Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.

PME Intrinsic Value
22.19 AUD
Overvaluation 83%
Intrinsic Value
Price AU$133.84
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett